PCVX vs PFE vs MRK vs GSK vs SNY

For growth investors, Sanofi (SNY) is the stronger pick with 5.

5% revenue growth year-over-year, versus -1. 6% for Pfizer Inc. (PFE). GSK plc (GSK) offers the better valuation at 6. 7x trailing P/E (10. 4x forward), making it the more compelling value choice. Analysts rate Vaxcyte, Inc. (PCVX) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, GSK plc (GSK) is the cheapest at 6.

7x versus Pfizer Inc. at 19. 5x. On forward P/E, Pfizer Inc. is actually cheaper at 8. 9x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: GSK plc wins at 0. 73x versus Merck & Co. , Inc. 's 1. 03x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Vaxcyte, Inc.

(PCVX) delivered a total return of +191. 8%, compared to -13. 3% for Pfizer Inc. (PFE). Over 10 years, the gap is even starker: MRK returned +166. 5% versus PFE's +29. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), GSK plc (GSK) is the lower-risk stock at 0.

46β versus Vaxcyte, Inc. 's 1. 07β — meaning PCVX is approximately 131% more volatile than GSK relative to the S&P 500. On balance sheet safety, Vaxcyte, Inc. (PCVX) carries a lower debt/equity ratio of 9% versus 111% for GSK plc — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Sanofi (SNY) is pulling ahead at 5.

5% versus -1. 6% for Pfizer Inc. (PFE). On earnings-per-share growth, the picture is similar: GSK plc grew EPS 348. 4% year-over-year, compared to -48. 2% for Vaxcyte, Inc.. Over a 3-year CAGR, SNY leads at 4. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Merck & Co.

, Inc. (MRK) is the more profitable company, earning 28. 1% net margin versus 0. 0% for Vaxcyte, Inc. — meaning it keeps 28. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MRK leads at 36. 2% versus 0. 0% for PCVX. At the gross margin level — before operating expenses — GSK leads at 72. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, GSK plc (GSK) is the more undervalued stock at a PEG of 0. 73x versus Merck & Co. , Inc. 's 1. 03x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Pfizer Inc. (PFE) trades at 8. 9x forward P/E versus 21. 9x for Merck & Co. , Inc. — 13. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PCVX: 61. 2% to $83. 00.

In this comparison, GSK (6.

6% yield), PFE (6. 5% yield), SNY (5. 1% yield), MRK (2. 9% yield) pay a dividend. PCVX does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Merck & Co.

, Inc. (MRK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 48), 2. 9% yield, +166. 5% 10Y return). Both have compounded well over 10 years (MRK: +166. 5%, PCVX: +96. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: PCVX is a small-cap quality compounder stock; PFE is a mid-cap income-oriented stock; MRK is a large-cap deep-value stock; GSK is a mid-cap deep-value stock; SNY is a mid-cap income-oriented stock. PFE, MRK, GSK, SNY pay a dividend while PCVX does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.